Nightstar Therapeutics (NASDAQ:NITE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm presently has a $14.00 price target on the stock. Zacks Investment Research‘s price objective would suggest a potential downside of 1.41% from the stock’s current price.

According to Zacks, “Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. “

Other equities research analysts also recently issued research reports about the stock. Leerink Swann lifted their price target on shares of Nightstar Therapeutics from $30.00 to $35.00 and gave the stock a “positive” rating in a research note on Monday, September 24th. UBS Group began coverage on shares of Nightstar Therapeutics in a research note on Friday, January 4th. They set a “buy” rating and a $21.00 price target on the stock. Cantor Fitzgerald began coverage on shares of Nightstar Therapeutics in a research note on Thursday, October 11th. They set an “overweight” rating and a $36.00 price target on the stock. Barclays began coverage on shares of Nightstar Therapeutics in a research note on Monday, December 17th. They set an “overweight” rating and a $28.00 price target on the stock. Finally, Mizuho reaffirmed a “buy” rating and set a $24.00 price target on shares of Nightstar Therapeutics in a research note on Tuesday, September 25th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Nightstar Therapeutics has an average rating of “Buy” and a consensus target price of $31.00.

Nightstar Therapeutics stock traded down $0.17 during midday trading on Wednesday, hitting $14.20. 400 shares of the stock were exchanged, compared to its average volume of 74,512. Nightstar Therapeutics has a 1 year low of $9.59 and a 1 year high of $29.55. The company has a market capitalization of $368.67 million, a price-to-earnings ratio of -8.69 and a beta of 3.34.

Nightstar Therapeutics (NASDAQ:NITE) last released its quarterly earnings results on Tuesday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.13. As a group, sell-side analysts predict that Nightstar Therapeutics will post -1.45 earnings per share for the current year.

In other news, insider Gregory Scott Robinson sold 14,764 shares of Nightstar Therapeutics stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $11.15, for a total value of $164,618.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David A. Fellows sold 8,733 shares of Nightstar Therapeutics stock in a transaction dated Monday, January 7th. The shares were sold at an average price of $12.98, for a total transaction of $113,354.34. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,328 shares of company stock valued at $291,734.

Several hedge funds and other institutional investors have recently bought and sold shares of NITE. Bank of America Corp DE acquired a new position in shares of Nightstar Therapeutics in the 2nd quarter valued at about $132,000. Partner Fund Management L.P. boosted its holdings in shares of Nightstar Therapeutics by 0.7% in the 2nd quarter. Partner Fund Management L.P. now owns 1,016,980 shares of the company’s stock valued at $16,272,000 after buying an additional 7,007 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Nightstar Therapeutics in the 3rd quarter valued at about $169,000. Janney Montgomery Scott LLC acquired a new position in shares of Nightstar Therapeutics in the 3rd quarter valued at about $204,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Nightstar Therapeutics in the 3rd quarter valued at about $214,000. 37.84% of the stock is owned by institutional investors and hedge funds.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.

Featured Article: How Short Selling Works

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.